Login to Your Account

Synlogic takes reverse route public, closes $42M series C

By Michael Fitzhugh
Staff Writer

Tuesday, May 16, 2017

Privately held Synlogic Inc., a company leveraging synthetic biology to genetically reengineer microbes, is going public via a reverse merger with troubled microRNA mimic pioneer Mirna Therapeutics Inc.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription